Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001864601 | SCV002143312 | uncertain significance | ALG12-congenital disorder of glycosylation | 2021-12-13 | criteria provided, single submitter | clinical testing | This variant is present in population databases (rs200490756, gnomAD 0.006%). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals affected with ALG12-related conditions. This sequence change replaces histidine, which is basic and polar, with tyrosine, which is neutral and polar, at codon 139 of the ALG12 protein (p.His139Tyr). |
Ambry Genetics | RCV002551126 | SCV003637054 | uncertain significance | Inborn genetic diseases | 2022-08-17 | criteria provided, single submitter | clinical testing | The c.415C>T (p.H139Y) alteration is located in exon 4 (coding exon 3) of the ALG12 gene. This alteration results from a C to T substitution at nucleotide position 415, causing the histidine (H) at amino acid position 139 to be replaced by a tyrosine (Y). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |